

# Johnson & Johnson Innovative Medicine Pipeline

## Key Events in 2024\*

### POTENTIAL APPROVALS US/EU

✓ US ✓ EU	<b>OPSUMIT (macitentan)</b> Pediatric Pulmonary Arterial Hypertension (TOMORROW)	✓ US ✓ EU	<b>DARZALEX (daratumumab)</b> Frontline multiple myeloma transplant eligible (PERSEUS)
✓ US ✓ EU	<b>OPSYNVI/YVANCI (macitentan/tadalafil STCT)</b> Pulmonary Arterial Hypertension	✓ US ✓ EU	<b>CARVYKTI (cilicabtagene autoleucel)</b> Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)
✓ US ✓ EU	<b>EDURANT (rilpivirine)</b> HIV pediatric 2-12 year old	✓ US ✓ EU	<b>RYBREVANT (amivantamab)</b> Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)
✓ US <sup>^</sup> ✓ EU	<b>BALVERSA (erdafitinib)</b> Urothelial Cancer (THOR)	✓ US ✓ EU	<b>RYBREVANT</b> Non Small Cell Lung Cancer 2L (MARIPOSA-2)
✓ US	<b>TREMFYA (guselkumab)</b> Ulcerative Colitis (QUASAR)	✓ US ✓ EU	<b>RYBREVANT / LAZCLUZE</b> Non Small Cell Lung Cancer (MARIPOSA)

### PLANNED SUBMISSIONS US/EU

✓ US ✓ EU	<b>TREMFYA (guselkumab)</b> Pediatric Juvenile Psoriatic Arthritis	✓ US ✓ EU	<b>RYBREVANT (amivantamab)</b> Subcutaneous (PALOMA-3)
✓ US ✓ EU	<b>TREMFYA (guselkumab)</b> Ulcerative Colitis (QUASAR)	✓ US ✓ EU	<b>DARZALEX (daratumumab)</b> Frontline multiple myeloma transplant eligible (PERSEUS)
✓ US ✓ EU	<b>TREMFYA (guselkumab)</b> Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓ US ✓ EU	<b>DARZALEX (daratumumab)</b> Frontline multiple myeloma transplant ineligible (CEPHEUS)
✓ US ✓ EU	<b>TREMFYA (guselkumab)</b> Crohn's Disease Subcutaneous Induction (GRAVITI)	✓ US ✓ EU	<b>DARZALEX (daratumumab)</b> Smoldering Multiple Myeloma (AQUILA)
✓ US ✓ EU	<b>SIMPONI (golimumab)</b> Pediatric Ulcerative Colitis	✓ EU	<b>IMBRUVICA (ibrutinib)</b> Frontline MCL (Triangle)
✓ EU	<b>STELARA (ustekinumab)</b> Pediatric Crohn's Disease	✓ US	<b>OPSUMIT (macitentan)</b> Pediatric Pulmonary Arterial Hypertension (TOMORROW)
✓ US	<b>TREMFYA (guselkumab)</b> Pediatric Psoriasis	✓ EU	<b>UPTRAVI (selexipag)</b> Pediatric Pulmonary Arterial Hypertension (SALTO)
✓ US ✓ EU	<b>TREMFYA (guselkumab)</b> Crohn's Disease (GALAXI)	✓ US	<b>SPRAVATO (esketamine) monotherapy</b> Treatment Resistant Depression (TRD4005)
		✓ US ✓ EU	<b>nipocalimab</b> Generalized Myasthenia Gravis
		✓ EU	<b>REKAMBYS</b> HIV Adolescents

### POTENTIAL CLINICAL DATA PRESENTATIONS<sup>1</sup>

Phase III	Phase I/ II
✓ <b>nipocalimab</b> Generalized Myasthenia Gravis	✓ <b>nipocalimab</b> Sjogren's Disease (DAHLIAS)
✓ <b>seltorexant</b> Adjunctive treatment for major depressive disorder with insomnia symptoms	✓ <b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b> Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ <b>SPRAVATO (esketamine)</b> Treatment Resistant Depression monotherapy (TRD4005)	✓ <b>TECVAYLI (teclistamab)</b> Trasplant-eligible Newly Diagnosed Multiple Myeloma (MajesTEC-5)
✓ <b>TREMFYA (guselkumab)</b> Crohn's Disease Subcutaneous Induction (GRAVITI)	
✓ <b>TREMFYA (guselkumab)</b> Crohn's Disease (GALAXI)	
✓ <b>TREMFYA (guselkumab)</b> Ulcerative Colitis (QUASAR)	
✓ <b>DARZALEX (daratumumab)</b> Frontline multiple myeloma transplant ineligible (CEPHEUS)	
✓ <b>DARZALEX (daratumumab)</b> Smoldering Multiple Myeloma (AQUILA)	
✓ <b>DARZALEX (daratumumab)</b> Amyloidosis (ANDROMEDA)	
✓ <b>RYBREVANT (amivantamab)</b> Subcutaneous (PALOMA-3)	

✓ = Achieved

<sup>1</sup> In order to be on key events clinical presentation, data must be presented at a major medical meeting. <sup>^</sup> BALVERSA US Full Approval

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of January 22, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

